文献速递自身炎症与 IgG4 相关病

阿那白滞素与卡那奴单抗治疗VEXAS综合征的疗效与安全性比较:国际多中心研究

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study.
PubMed 文献 · Arthritis Rheumatol · 2025-12-12

该国际多中心研究纳入47例VEXAS综合征男性患者,比较阿那白滞素(44例)与卡那奴单抗(9例)的临床应答、药物生存期及不良事件。卡那奴单抗1个月和3个月整体应答率分别为100%和78%,均高于阿那白滞素的34%和22%;卡那奴单抗300mg/月药物生存期54个月,阿那白滞素仅1个月。作者认为卡那奴单抗临床应答和药物生存期更优、不良事件更少。

要点

  • 3个月整体应答:卡那奴单抗78% vs 阿那白滞素22%(P=0.001),多因素分析OR 28.8。
  • 卡那奴单抗300mg/月药物生存期54个月,阿那白滞素1个月(P=0.01)。
  • 注射部位反应仅见于阿那白滞素组(47% vs 0%,P=0.006)。

核心结论

  • 作者认为卡那奴单抗相比阿那白滞素表现出更优的临床应答和药物生存期,且不良事件更少。
  • 作者提出每月卡那奴单抗300mg可考虑作为VEXAS综合征患者有效的减少激素用量的治疗选择。

研究设计与样本

  • 国际多中心研究,纳入来自法国、以色列和意大利的VEXAS综合征患者,接受白细胞介素-1抑制治疗。
  • 共纳入47例男性VEXAS综合征患者;44例接受阿那白滞素,9例接受卡那奴单抗,6例在不同时间点使用过两种药物。
  • 整体应答定义为无炎症症状且激素剂量和C反应蛋白下降≥50%;采用多因素回归分析相关变量,Kaplan-Meier法和log-rank检验分析药物生存期,Cox回归模型分析相关因素。

主要发现

  • 1个月整体应答率:阿那白滞素组34% vs 卡那奴单抗组100%(P<0.001)。
  • 3个月整体应答率:阿那白滞素组22% vs 卡那奴单抗组78%(P=0.001)。
  • 多因素分析中,卡那奴单抗治疗与3个月达到整体应答的更高OR相关(OR 28.8,95%CI 3.0-273.9;P=0.004)。
  • 中位药物生存期:卡那奴单抗300mg/月为54个月(IQR 30-56),卡那奴单抗150mg/月为7个月(IQR 4-8),阿那白滞素为1个月(IQR 1-2.5)(P=0.01)。
  • 注射部位反应仅记录于阿那白滞素组(47% vs 0%;P=0.006);感染在阿那白滞素组更常见(31% vs 11%;P=0.3)。

临床怎么用

  • 作者提出每月卡那奴单抗300mg可考虑作为VEXAS综合征患者有效的减少激素用量的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. METHODS: This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with interleukin-1 inhibition. Global response (GR) was defined as the absence of inflammatory symptoms and ≥50% decrease in steroid dose and C-reactive protein. Multiple regression analysis was performed to identify associated variables. Drug survival was analyzed using Kaplan-Meier plots and log-rank test, with Cox regression models for associated factors. RESULTS: We included 47 male patients with VEXAS; 44 received anakinra and 9 received canakinumab, with 6 patients using both at different time points. GR at 1 month was 34% for anakinra and 100% for canakinumab (P < 0.001) and 22% and 78% at 3 months, respectively (P = 0.001). Treatment with canakinumab was associated with a higher odds ratio (OR) of achieving GR at 3 months (OR 28.8, 95% confidence interval 3.0-273.9; P = 0.004) in a multivariable analysis. Median drug survival was 54 (interquartile range [IQR] 30-56) months for canakinumab at 300 mg/month compared with 7 (IQR 4-8) months for canakinumab 150 mg/month and 1 (IQR 1-2.5) months for anakinra (P = 0.01). Injection-site reactions were only recorded for the anakinra group (47 vs 0%; P = 0.006), whereas infections were more frequent in the anakinra group (31% and 11%; P = 0.3). CONCLUSION: Canakinumab demonstrated superior clinical response and drug survival with fewer adverse events compared with anakinra. Monthly canakinumab 300 mg may be considered as an effective steroid-sparing therapeutic option for patients with VEXAS.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Eviatar T, Capelusnik D, Campochiaro C, et al. Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study. Arthritis Rheumatol. 2025. PMID: 40977434. doi:10.1002/art.43384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。